Physician profile
Ken Fujioka
NPI 1811007255
$747,377.21
in general payments reported to CMS, 2019-2025
38 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125K · 2020: $86K · 2021: $93K · 2022: $76K · 2023: $71K · 2024: $157K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $297K · Consulting Fee: $38K · Travel and Lodging: $22K · Food and Beverage: $9,127 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $297,490.64 |
| Consulting Fee | $38,365.00 |
| Travel and Lodging | $22,454.63 |
| Food and Beverage | $9,126.84 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $469,533.77 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $184,366.57 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $29,972.95 | 2020-2023 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,421.79 | 2019-2025 | |
| Amgen INC. | $23,900.18 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $3,992.76 | 2019 | |
| Currax Pharmaceuticals LLC | $2,384.90 | 2019-2024 | Contrave |
| Rhythm Pharmaceuticals, INC. | $2,196.44 | 2021-2024 | Imcivree, Imcivree |
| Novo Nordisk As | $1,840.00 | 2019-2023 | |
| Shionogi INC | $1,042.50 | 2023 | |
| Kvk-Tech, INC. | $436.21 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $398.12 | 2019-2022 | |
| Shire North American Group INC | $262.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $162.97 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $157.36 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $143.97 | 2019-2025 | Qsymia |
| Abbott Laboratories | $142.22 | 2019-2023 | Freestyle Libre 3 |
| Eisai INC. | $116.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $92.93 | 2019-2021 | |
| Corcept Therapeutics | $90.87 | 2019 | |
| Merck Sharp & Dohme LLC | $77.55 | 2019-2020 | |
| Ibsa Pharma INC. | $71.72 | 2019-2022 | |
| Amarin Pharma, INC. | $68.52 | 2019 | |
| Insulet Corporation | $67.87 | 2019-2020 | |
| Medtronic, INC. | $58.30 | 2022-2024 | Minimed 780g |
| Horizon Therapeutics Plc | $57.67 | 2021-2023 | Tepezza |
| Abbvie INC. | $56.17 | 2019-2020 | |
| Daiichi Sankyo INC. | $36.88 | 2019 | |
| Cequr Corporation | $33.79 | 2022 | |
| Evoke Pharma, INC. | $27.36 | 2025 | |
| Olympus America INC. | $26.29 | 2022 | |
| Radius Health, INC. | $25.85 | 2025 | |
| Ethicon US, LLC | $23.63 | 2024 | Linx Reflux Management System |
| Ascendis Pharma Endocrinology INC | $23.45 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.32 | 2022 | |
| Mannkind Corporation | $19.10 | 2019 | |
| Recordati_rare_diseases_inc. | $14.07 | 2021 | |
| Inspire Medical Systems, INC. | $13.91 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Fujioka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.